Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded to “Hold” at Wall Street Zen

Oric Pharmaceuticals (NASDAQ:ORIC) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other research analysts have also weighed in on the company. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Oric Pharmaceuticals in a research report on Tuesday. Citigroup increased their target price on Oric Pharmaceuticals from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday. Evercore began coverage on Oric Pharmaceuticals in a research report on Thursday, November 20th. They issued an “outperform” rating and a $25.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Thursday, January 22nd. Finally, HC Wainwright raised their price objective on shares of Oric Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $20.20.

Oric Pharmaceuticals Price Performance

Shares of NASDAQ ORIC opened at $13.45 on Friday. Oric Pharmaceuticals has a 1 year low of $3.90 and a 1 year high of $14.93. The firm has a 50-day moving average of $10.39 and a 200 day moving average of $11.00. The stock has a market cap of $1.35 billion, a P/E ratio of -8.85 and a beta of 1.35.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04. Research analysts expect that Oric Pharmaceuticals will post -2.17 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Pratik S. Multani sold 10,720 shares of Oric Pharmaceuticals stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $9.06, for a total value of $97,123.20. Following the completion of the sale, the insider directly owned 68,149 shares in the company, valued at $617,429.94. The trade was a 13.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Dominic Piscitelli sold 52,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total transaction of $702,520.00. Following the transaction, the chief financial officer directly owned 68,148 shares of the company’s stock, valued at $920,679.48. The trade was a 43.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 106,814 shares of company stock worth $1,199,135. 6.82% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Oric Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. Orbimed Advisors LLC raised its stake in Oric Pharmaceuticals by 305.0% during the 3rd quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock valued at $43,701,000 after buying an additional 2,742,475 shares during the last quarter. Paradigm Biocapital Advisors LP bought a new stake in shares of Oric Pharmaceuticals in the fourth quarter worth $19,642,000. State Street Corp increased its position in Oric Pharmaceuticals by 77.1% during the fourth quarter. State Street Corp now owns 4,258,397 shares of the company’s stock valued at $34,834,000 after acquiring an additional 1,854,458 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Oric Pharmaceuticals by 48.8% in the third quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company’s stock valued at $55,802,000 after acquiring an additional 1,525,445 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Oric Pharmaceuticals by 3,646.1% in the second quarter. JPMorgan Chase & Co. now owns 1,335,448 shares of the company’s stock valued at $13,555,000 after acquiring an additional 1,299,799 shares during the period. Institutional investors own 95.05% of the company’s stock.

Trending Headlines about Oric Pharmaceuticals

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised quarterly and FY2026 EPS estimates, narrowed the FY loss forecast (to ($1.28) from ($1.52)), kept a “Buy” rating and raised its price target to $25 — a material analyst upgrade supporting upside. Read More.
• Positive Sentiment: Oric reported a Q4 earnings beat (EPS -$0.30 vs. -$0.34 consensus), which acted as a near-term catalyst and likely drove recent buying interest. Read More.
• Positive Sentiment: Multiple broker actions (Wedbush Outperform; Piper Sandler, JPMorgan and others with overweight/buy calls and higher targets) have created a bullish analyst consensus — Zacks highlights the mean price target implying ~58% upside, which can attract momentum buyers. Read More.
• Neutral Sentiment: Consensus still shows multi-quarter losses (current full‑year consensus ~($2.17) per share), so the stock’s upside depends on continued clinical progress, margin improvement and execution. Read More.
• Neutral Sentiment: Institutional ownership is very high (~95%); while this can stabilize the stock, it may also limit new institutional inflows unless conviction strengthens. Read More.
• Negative Sentiment: CFO Dominic Piscitelli sold 52,000 shares (~$702.5k at ~$13.51), cutting his stake by ~43% — insider selling can be perceived negatively and may temper the rally. SEC Form 4: Read More.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.